Search Results
Search results for "Ya-Tzu Li"
Results found for "Ya-Tzu Li"
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
structural analysis of these complexes revealed two important aspects: the specific residues involved in ligand between the receptor-Gs and receptor-Gi complexes, suggesting that the selectivity of the G-protein lies Likewise, in this work the authors identify for the first time the specific amino acids that modulate subfamilies of class A GPCRs and potential therapeutic targets that are activated by the same endogenous ligand Check the original article at this link https://pubmed.ncbi.nlm.nih.gov/35714614/ *Above information
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
But drift does not live there. It lives in what is never questioned because it feels acceptable at the time. 👉 This kind of failure What looks like progress is often motion without alignment. The strategic advantage lies in leadership attention, not precision.
- Chemokine receptor-targeted drug discovery: progress and challenges
At a molecular level, different ligands bind to the same receptor and vice-versa (Marcuzzi et al. 2018 Drug discovery is shifting towards the development of biased ligands, which promote the engagement of and signaling patterns, by modulating ligand binding, as well as G-protein coupling or interaction with , unlike most of the class A GPCRs ligands that are small molecules or short peptides. Overall, the future potential lies in using different therapeutic modalities to modulate the stromal
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
GPCR dimers in drug discovery referring to important conformational changes, allosteric properties, ligand Interestingly, the amplitude of the conformational changes due to ligand binding is limited at these Li, et al 2012; B. Bai, et al. 2014; B. Ji, et al. 2020; L. Wan, 2020). Various studies reported that the biased properties of ligands and receptors are a consequence of GPCR Junke Liu et al. recently provided key insights into GPCR oligomerization and biased signalling, using
- Overview of adhesion GPCRs self-activation
Structurally they characterize by a long extracellular region of adhesion-like domains which modulate structures provided the basis for the mechanism of self-activation of aGPCRs supporting the encrypted ligand possible to know that ADGRL3 can activate and form stable complexes with Gs, Gi, Gq, and G12, where like binding pocket and helps to stabilize the tethered ligand-receptor. Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,
- Glyco-sulfo hotspots in the chemokine receptor system
N-terminal PTMs on chemokine receptors The interaction of chemokine receptors with their cognate chemokine ligands This PTM has been shown to be heterogeneous [Li X et al. 2018; Scurci I et al. 2021) and to improve the From the five GalNAc-Ts, GalNAc-T1 was shown to be the most likely candidate for directly glycosylating pairs and potentially cell line and tissue tested. In addition, tyrosine sulfation is heterogenous between cell lines or even on the same cell (Scurci I
- GPCRs at Discovery on Target 2026
into the broader Lead Generation Strategies program, sitting alongside covalent chemistry, DNA-encoded libraries GPCRs do not live in isolation, and neither do the people working on them. receptor, using mitragynine pseudoindoxyl and a newly identified allosteric pocket to tune signaling like unusually wide slice of the field: Antifibrotic and anti-inflammatory targets, including GPR68 Biased ligand Terry's Corner is our room where he breaks down receptor pharmacology, functional selectivity, and ligand
- The GPCR antibody signal that should have been there
none of a particular receptor, a clean negative control, and yet several commercial antibodies still lit Chia-Yi Lin, began. A word that admits what it doesn’t know Much of that trust problem, Dr. Lin arrived from a different door. Lin insist, are not the vendor but the researchers who run these systems every day. Listen to the full conversation with Dr. Ball and Dr. Lin Watch the webinar recording with Dr. Ball
- The Boston Happy Hour: What Happens When GPCR Scientists Enter the Cafe
We had trainees and CSOs standing next to each other, talking like peers. Take a look at this little montage we created. I picked the pack that was the first at the top of the list with the best reviews and fast delivery. It felt like a place that wanted a community event to happen inside it. GPCR ecosystem is where the community lives year-round, the Weekly News, the Masterclass library, and
- Choosing the Right GPCR Calcium Assay Readout for Measuring Receptor Activation
For Gαq/11-coupled receptors, ligand binding stimulates phospholipase C, leading to IP3 production and In this article, you'll learn: How GPCR calcium signaling assays work The advantages and limitations ChemiSCREEN™ Cell Lines ChemiSCREEN cell lines are engineered to enable calcium-based functional analysis ChemiBRITE® Cell Lines ChemiBRITE cell lines utilize a similar force-coupling strategy but additionally For more information on Eurofins DiscoverX calcium cell lines, cell lines assays, thaw-and-use frozen
- Amylin Receptor Signaling: Three Receptors From One, and How to Profile Each
What amylin receptor signaling looks like when you can measure it Resolving this used to mean assembling These systems provide quantitative readouts of ligand activity across both cAMP signaling and β-arrestin GPCR's Strategic Partner, across cell line assays, ready-to-use eXpress kits, membrane preparations, He walks through why a standard cell line reports calcitonin instead of amylin, and how the team built a line that finally reads real amylin pharmacology.
- Why GPCR Biologic Drugs Stabilize Active States Small Molecules Struggle to Reach
To produce agonism, a ligand must do more than occupy the binding pocket. The conformational outcome accessible from it depends on how much of the binding architecture a ligand Family B GPCRs have a rich history of allosteric ligands that produce activation. A series that shows good binding and weak activation, repeatedly, may be encountering the limit of what Terry's Corner is the room where pharmacologists work through frameworks like these alongside Dr.
- GPCR Drug Discovery Summit 2026: What to Expect in Boston — and How to Register
agenda highlights, who's attending, our exclusive discount code, and speaker interviews as they go live include: Abalone Bio · AbbVie · Biagon · Biolexis Therapeutics · Confo Therapeutics · Eli Lilly day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly
- GPCR Happy Hour Boston 2026 — April 29 | Dr. GPCR Community Event
Space is limited to 50 scientists. Food and one drink ticket included. Cash bar available. cryo-EM capabilities, including epitope mapping and structure determination of challenging targets like conversation with their CSO Giovanna Scapin Revvity | Founding Co-Host Revvity is a global leader in life Their deorphanisation track record (17 identified natural receptor-ligand pairs) speaks to the depth Space is limited to 50 scientists — registration is required.
- Five GPCR Masterclasses Before The Summer
Five live Masterclasses are scheduled before summer break. Two Partner Webinars are lining up. Explore the library ➤ Five Live GPCR Masterclasses Before Summer All included in Premium , each one a More live Masterclasses coming in the fall. Premium members have full access to the pre-summer Masterclass lineup, the live sessions, and the expanding on-demand library.
- Understanding Biased Signaling in GPCRs
Join us live, April 9, 2026, 10 am EST. Join us live, April 16, 2026, 10 am EST. Read analysis ➤ Computational descriptions of ligand bias remain central to linking structural motion Explore the library ➤ What Members Say “Dr. Library, alongside curated research and industry updates.
- GPCR Selectivity Beyond the Receptor
Biased signaling frameworks centered on receptor conformations have a structural limitation when selectivity Both layers are examined in the April live sessions with our expert instructors. discussion âžž Premium Members get live access, full replay, and year-round ecosystem access. From the Masterclass Library This week's featured course from the Masterclass Library: GPCR Projects: Premium members access the full Masterclass library, weekly curated publications, live sessions, and
- Dr. GPCR and GeneTex Partner to Engage the Community on Anti-GPCR Antibody Challenges
recognized: the specificity and reliability of anti-GPCR antibodies, and the downstream impact these limitations requires continued attention to antibody specificity, validation strategies, and transparent discussion of limitations By explicitly acknowledging these challenges, the partnership aligns with broader efforts across the life sciences to improve data reproducibility by addressing limitations at the level of research tools.
- Quantifying Receptor Selectivity in Modern Drug Discovery
It is always ligand × system. In the full lecture, Dr. True receptor selectivity must transcend the cell line. A “silent” ligand may be system-limited. More often, one ligand is partial. Now EC₅₀ values alone are insufficient. Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity
- The Hidden Cost of Ambition in Biotech Leadership
What feels like momentum can quietly become dilution. More programs. Broader roadmaps. What Strategic Discipline Actually Looks Like in Practice Strategic discipline does not mean shrinking look for ambition that is ambitious but engineered. âś… In other words, strategic discipline does not limit If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention
- The Real Cost of Strategic Overload in Biotech
👉 In early-stage biotech, activity often feels like strategy. On the surface, this looks like a strength. There is movement across the board. Capital is limited. Leadership attention is stretched. Internally, this feels like diversification. Letting go of a program can feel like abandoning potential value.
- Dr. GPCR and Eurofins DiscoverX Join Forces to Accelerate GPCR Drug Discovery
action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem
- The Moment Biotech Founders Realize the Money Is Gone
. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting failure.
- Better GPCR Drug Discovery Decisions Start With Structured Learning
This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly Legacy courses will migrate into this format over the coming weeks, with live courses returning in March What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST.
- Why Fundraising Mistakes Kill Strong Biotech Startups
In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold The pressure mounts further as regulators require detection and characterization of these liabilities—even Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
Latest breakthroughs :  Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition Listeners will gain perspective on: Assay choice as strategy , not convenience. Leadership decisions  that keep multidisciplinary teams aligned. 👉 Listen to the full conversation ➤
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue Drug-Like Properties: The Real Starting Point PK does not begin at dosing—it begins with physicochemical Transporter affinity and solubility limits routinely sabotage otherwise strong ligands Effective PK Kenakin introduces mass-balance thinking and metabolic accounting  to proactively manage liabilities your fingertips : Explore the full library ➤
- The Hidden Cost of Unclear Biotech Positioning
They emphasize different elements depending on who is listening, which creates confusion instead of clarity This puts the burden of synthesis on the listener , who may not share the same context or priorities. External conversations become easier because the listener understands what they are being asked to evaluate When that decision is made explicitly, depth stops being a liability. They respond to questions as they arise, adjusting emphasis depending on who is listening.
- How Early Strategic Decision Making Creates Alignment and Better Results
If you have ever wondered why effort does not always translate into results, the answer often lives much Tradeoffs have already been accepted. 👉 What looks like a performance gap late in the year is often What once felt like optionality quietly turns into constraint. This is the phase where choices feel lightweight, but their impact is anything but. With alignment, execution starts to feel lighter, faster, and more coherent.

























